Clinical, genetic, and proteomic characteristics of type 2 diabetes complicated with exogenous insulin antibody syndrome: a case-control study
Authors' conclusion
IA-positive patients with remarkably elevated ICPR are prone to glycemic variability and should be evaluated for the diagnosis of EIAS. In this pilot study with limited sample size, EIAS is associated with unique HLA-DR-DQ risk haplotypes and enhanced immunoinflammatory response.
Study context
- Population
- T2D patients receiving insulin therapy, IA-positive and IA-negative177 IA-positive, 177 IA-negative
- Comparison
- T2D with exogenous insulin antibody syndrome (EIAS) vs IA-positive ICPR ≤ 1 vs IA-negative
- EIASn = 46
- IA-negativen = 177reference
- Outcome
- Clinical, genetic and proteomic characteristics of EIAS
Methodological detailspilot study, human leukocyte antigen (HLA) genotyping and plasma proteomic analysis (Olink) in EIAS cases
- Pilot study
- HLA genotyping and plasma proteomic analysis (Olink) in EIAS cases
Main finding
As reported in the abstract
- Differentially expressed proteins in EIAS
- 9
Observational data: associations, not effects.
Original publication
Clinical, genetic, and proteomic characteristics of type 2 diabetes complicated with exogenous insulin antibody syndrome: a case-control study. Diabetes Res Clin Pract. Published 20 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →